Oculis Holding AG (NASDAQ:OCS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Oculis Holding AG (NASDAQ:OCS) have been given a consensus recommendation of “Moderate Buy” by the eight research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $43.8571.

Several equities research analysts have commented on OCS shares. Wall Street Zen cut shares of Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Stifel Nicolaus boosted their price target on shares of Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $44.00 target price on shares of Oculis in a report on Monday. Finally, Needham & Company LLC upped their target price on shares of Oculis from $36.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, March 4th.

Oculis Trading Up 4.2%

Shares of NASDAQ:OCS opened at $28.61 on Tuesday. The company’s 50-day moving average price is $27.29 and its two-hundred day moving average price is $23.62. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.96 and a quick ratio of 5.96. Oculis has a one year low of $16.00 and a one year high of $30.68. The stock has a market capitalization of $1.66 billion, a PE ratio of -12.60 and a beta of 0.48.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.08). Oculis had a negative return on equity of 62.12% and a negative net margin of 8,173.41%.The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.14 million. On average, equities analysts forecast that Oculis will post -2.17 EPS for the current fiscal year.

Institutional Investors Weigh In On Oculis

A number of institutional investors and hedge funds have recently modified their holdings of the company. Perceptive Advisors LLC bought a new stake in shares of Oculis in the 4th quarter valued at about $9,862,000. Millennium Management LLC bought a new stake in shares of Oculis in the 4th quarter valued at about $312,000. NEXTBio Capital Management LP bought a new stake in shares of Oculis in the 4th quarter valued at about $2,991,000. Marshall Wace LLP bought a new stake in shares of Oculis in the 4th quarter valued at about $914,000. Finally, Alyeska Investment Group L.P. raised its holdings in shares of Oculis by 152.3% in the 4th quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock valued at $6,617,000 after purchasing an additional 200,000 shares during the period. 22.30% of the stock is owned by institutional investors.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.